{"id":"NCT00586612","sponsor":"GlaxoSmithKline","briefTitle":"Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm Infants","officialTitle":"Immunogenicity & Safety Study in Preterm & Full-term Infants of GSK Biologicals' Hib-MenC Vaccine, Menitorix™ Co-administered With Infanrix™ Penta & Prevenar™ at 2, 4, 6 Months & as a Booster With Infanrix™ IPV & Prevenar™ at 16-18 Months","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-12-01","primaryCompletion":"2008-12-30","completion":"2008-12-30","firstPosted":"2008-01-04","resultsPosted":"2010-01-22","lastUpdate":"2018-08-27"},"enrollment":313,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Haemophilus Influenzae Type b","Neisseria Meningitidis"],"interventions":[{"type":"BIOLOGICAL","name":"Menitorix™","otherNames":[]},{"type":"BIOLOGICAL","name":"Infanrix™ penta","otherNames":[]},{"type":"BIOLOGICAL","name":"Prevenar™","otherNames":[]},{"type":"BIOLOGICAL","name":"Infanrix™ IPV","otherNames":[]}],"arms":[{"label":"Preterm group","type":"EXPERIMENTAL"},{"label":"Full-term group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this Phase IIIb study is to evaluate the immunogenicity, reactogenicity \\& safety of GSK Biologicals' Hib-MenC vaccine (Menitorix™) when co-administered with GSK Biologicals' DTPa-HBV-IPV vaccine (Infanrix™ penta) \\& Wyeth's 7-valent pneumococcal conjugate vaccine (Prevenar™) in preterm infants as a 3-dose primary vaccination course during the first 6 months of life (at 2, 4, 6 months of age) and of a booster dose of Menitorix™ when co-administered with GSK Biologicals' DTPa-IPV vaccine (Infanrix IPV) and Wyeth's Prevenar in the second year of life (16-18 months of age). The control is a group of full-term infants receiving the same vaccines. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.","primaryOutcome":{"measure":"Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 0.15 Micrograms Per Milliliter (µg/mL)","timeFrame":"One month after the third vaccination","effectByArm":[{"arm":"Preterm Group","deltaMin":139,"sd":null},{"arm":"Full-term Group","deltaMin":141,"sd":null}],"pValues":[]},"eligibility":{"minAge":"8 Weeks","sex":"ALL","healthyVolunteers":true,"inclusionCount":7,"exclusionCount":16},"locations":{"siteCount":8,"countries":["Spain"]},"refs":{"pmids":[],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":22,"n":163},"commonTop":["Irritability/fussiness","Redness","Drowsiness","Pain","Swelling"]}}